Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003) | NCT00616070 | Trialant
CompletedInterventionalPhase 3Updated Jun 30, 2011
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)
ClinicalTrials.gov ID
NCT00616070
Lead Sponsor
Sirion Therapeutics, Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
120Estimated
Last Update Posted
Jun 30, 2011Estimated
Start Date
Dec 2007
Primary Completion Date
Mar 2008Actual
Completion Date
Mar 2008Actual
Brief Summary
The purpose of this phase III study is to determine the safety and efficacy of difluprednate in the management of inflammation following ocular surgery.
Inflammation
Difluprednate
Placebo
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Scheduled for unilateral ocular surgery.
Exclusion Criteria:
Systemic administration of any corticosteroid or immunosuppressive drug in the 2 weeks prior to study enrollment.